Compare NMTC & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NMTC | JSPR |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2M | 26.3M |
| IPO Year | 2010 | 2019 |
| Metric | NMTC | JSPR |
|---|---|---|
| Price | $1.46 | $0.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | $11.90 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 818.0K | 548.4K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.43 | 19.22 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,097,692.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $31.90 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 163.47 | N/A |
| 52 Week Low | $0.55 | $0.32 |
| 52 Week High | $5.40 | $2.69 |
| Indicator | NMTC | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 33.50 | 39.66 |
| Support Level | $1.42 | $0.55 |
| Resistance Level | $1.98 | $1.01 |
| Average True Range (ATR) | 0.24 | 0.05 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 0.00 | 22.18 |
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.